Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 14/20 | 0.93 |
| ▸ | TNIK | Q9UKE5 | 8/20 | 0.93 |
| ▸ | IKBKB | O14920 | 2/20 | 0.93 |
| ▸ | CHUK | O15111 | 2/20 | 0.93 |
| ▸ | ABL1 | P00519 | 2/20 | 0.93 |
| ▸ | INSR | P06213 | 2/20 | 0.93 |
| ▸ | CDK2 | P24941 | 2/20 | 0.93 |
| ▸ | FLT3 | P36888 | 2/20 | 0.93 |
| ▸ | SGK1 | O00141 | 1/20 | 0.93 |
| ▸ | AURKA | O14965 | 1/20 | 0.93 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.93 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.93 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.93 |
| ▸ | LCK | P06239 | 1/20 | 0.93 |
| ▸ | CDK1 | P06493 | 1/20 | 0.93 |
| ▸ | IGF1R | P08069 | 1/20 | 0.93 |
| ▸ | MET | P08581 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | SRC | P12931 | 1/20 | 0.93 |
| ▸ | FLT1 | P17948 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30529951 | 0.96 | MAP3K11 (1.00) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL722076 | 0.96 | MAP3K11 (1.00) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL30529948 | 0.96 | MAP3K11 (1.00) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL30529950 | 0.96 | MAP3K11 (1.00) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL30529949 | 0.96 | MAP3K11 (1.00) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL15758725 | 0.91 | MAP3K11 (0.83) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL12067524 | 0.89 | MAP3K11 (1.00) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL12067515 | 0.88 | MAP3K11 (0.84) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL15165529 | 0.87 | MAP3K11 (0.83) | MAP3K11TNIKIKBKBCHUKABL1 | |
| SCHEMBL25153323 | 0.87 | MAP3K11 (0.84) | MAP3K11TNIKIKBKBCHUKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-01-28 | — | — | US | disclosed |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-01-28 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| CN-103153994-A | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIV ROCHESTER | 2013-06-12 | — | — | CN | disclosed |
| EP-2576549-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | University of Rochester (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2379561-A2 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885TNIK 178/4885IKBKB 476/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | MAP3K11 45/4885TNIK 314/4885IKBKB 487/4885 |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885TNIK 178/4885IKBKB 476/4885 |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885TNIK 178/4885IKBKB 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.